Noticeably, the most significant upregulation of FBXW9 was observed in invasive breast carcinoma (BRCA) (p = 9.10 × 10−19), followed by colon adenocarcinoma (COAD) (p = 2.30 × 10−18), bladder urothelial carcinoma (BLCA) (p = 7.60 × 10−10), and 11 other cancer types (p < 0.001 for all) (Figure 1C). Here, FBXW9 is linked to bladder transitional cell carcinoma.